PMID- 26085003
OWN - NLM
STAT- MEDLINE
DCOM- 20160511
LR  - 20181202
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 29
IP  - 4
DP  - 2015 Jul-Aug
TI  - Immunomodulatory effect of tonsil-derived mesenchymal stem cells in a mouse model 
      of allergic rhinitis.
PG  - 262-7
LID - 10.2500/ajra.2015.29.4216 [doi]
AB  - BACKGROUND: Although several studies have claimed that mesenchymal stem cells 
      (MSC) derived from human tissues can ameliorate allergic airway inflammation, the 
      immunomodulatory mechanism of MSCs remains unclear. OBJECTIVE: We aimed to 
      determine the effects and the underlying mechanism of tonsil-derived MSCs (T-MSC) 
      on allergic inflammation compared with adipose tissue-derived stem cells (ASC) in 
      a mouse model of allergic rhinitis (AR). METHODS: MSCs were isolated from human 
      palatine tonsil (T-MSC) and the surface markers were analyzed. The effect of 
      T-MSCs was evaluated in 24 BALB/c mice that were randomly divided into four 
      groups (negative control group, positive control group, T-MSC group, and ASC 
      group). MSCs were administered intravenously to ovalbumin (OVA) sensitized mice 
      (T-MSC and ASC groups) on days 18 to 23, and subsequent OVA challenge was 
      conducted daily from days 24 to 28. Several parameters of allergic inflammation 
      were assessed. RESULTS: T-MSC and ASC had similar characteristics in surface 
      markers. Intravenous injection of T-MSC significantly reduced allergic symptoms, 
      eosinophil infiltration, serum total, and OVA-specific immunoglobulin E (IgE), 
      and the nasal and systemic T-helper (Th) 2 cytokine profile. Further analysis 
      revealed that nasal innate cytokines, such as interleukin (IL) 25 and IL-33, and 
      chemokines, such as CCL11, CCL24, induction was suppressed in T-MSCs injected 
      groups, which explained their underlying mechanism. In addition, the T-MSC group 
      had more inhibition of allergic inflammation than did the ASC group, which might 
      be attributed to the more proliferative activity of T-MSC. CONCLUSION: 
      Administration of T-MSC effectively reduced allergic symptoms and inflammatory 
      parameters in the mouse model of AR. T-MSC treatment reduced Th2 cytokines and 
      OVA-specific IgE secretion from B cells. In addition, innate cytokine (IL-25 and 
      IL-33) expression and eotaxin messenger RNA expression was inhibited in the nasal 
      mucosa, which is suggestive of the mechanism of reduced allergic inflammation. 
      Therefore, T-MSC treatment is potentially an alternative therapeutic modality in 
      AR.
FAU - Samivel, Ramachandran
AU  - Samivel R
AD  - Department of Otorhinolaryngology, Dankook University College of Medicine, 
      Cheonan, Korea.
FAU - Kim, Eun Hee
AU  - Kim EH
FAU - Chung, Young-Jun
AU  - Chung YJ
FAU - Mo, Ji-Hun
AU  - Mo JH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150616
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
SB  - IM
MH  - Adipose Tissue/immunology
MH  - Animals
MH  - Disease Models, Animal
MH  - Humans
MH  - *Immunomodulation
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Mesenchymal Stem Cells/*immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nasal Mucosa
MH  - Palatine Tonsil/immunology
MH  - Random Allocation
MH  - Rhinitis, Allergic/immunology/*surgery
MH  - Treatment Outcome
EDAT- 2015/06/19 06:00
MHDA- 2016/05/12 06:00
CRDT- 2015/06/19 06:00
PHST- 2015/06/19 06:00 [entrez]
PHST- 2015/06/19 06:00 [pubmed]
PHST- 2016/05/12 06:00 [medline]
AID - content-4216 [pii]
AID - 10.2500/ajra.2015.29.4216 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2015 Jul-Aug;29(4):262-7. doi: 10.2500/ajra.2015.29.4216. 
      Epub 2015 Jun 16.